Blinded and uniform cause of death verification in a lung cancer CT screening trial

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 522-525

  Horeweg, N ^a   van Klaveren, R J ^a   Groen, H J M ^b   Lammers, J W J ^c   Weenink, C ^d   Nackaerts, K ^e   Mali, W ^c   Oudkerk, M ^b   de Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Kennemer Gasthuis Haarlem ^*  (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Agreement; Cause of death; Death certificates; Death review; Lung cancer; Screening

Indexed keywords

ADULT; AGED; ANTEMORTEM DIAGNOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOLOGY; DEATH CERTIFICATE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPPA STATISTICS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY;

AGED; CAUSE OF DEATH; DEATH CERTIFICATES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84865162143     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.018     Document Type: Article

References (20)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
3. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365(5):395-409.
4. van Klaveren R.J., Oudkerk M., Prokop M., Scholten E.T., Nackaerts K., Vernhout R., et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009, 361(23):2221-2229.
5. Black W.C., Haggstrom D.A., Welch H.G. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002, 94(3):167-173.
6. Harteloh P., de Bruin K., Kardaun J. The reliability of cause-of-death coding in The Netherlands. Eur J Epidemiol 2010, 25(8):531-538.
7. Maudsley G., Williams E.M. " Inaccuracy" in death certification-where are we now?. J Public Health Med 1996, 18(1):59-66.
8. Albertsen P.C., Walters S., Hanley J.A. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 2000, 163(2):519-523.
9. Makinen T., Karhunen P., Aro J., Lahtela J., Maattanen L., Auvinen A. Assessment of causes of death in a prostate cancer screening trial. Int J Cancer 2008, 122(2):413-417.
10. Otto S.J., van Leeuwen P.J., Hoekstra J.W., Merckelbach J.W., Blom J.H., Schroder F.H., et al. Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?. Eur J Cancer 2010, 46(17):3061-3067.
11. Doria-Rose V.P., Marcus P.M., Miller A.B., Bergstralh E.J., Mandel J.S., Tockman M.S., et al. Does the source of death information affect cancer screening efficacy results?. A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials 2010, 7(1):69-77.
12. Doria-Rose V.P., Marcus P.M. Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. Lung Cancer 2009, 63(2):295-300.
13. Ederer F., Geisser M.S., Mongin S.J., Church T.R., Mandel J.S. Colorectal cancer deaths as determined by expert committee and from death certificate: a comparison. The Minnesota Study. J Clin Epidemiol 1999, 52(5):447-452.
14. Chamberlain J., Coleman D., Ellman R., Moss S. Verification of the cause of death in the trial of early detection of breast cancer. UK Trial of Early Detection of Breast Cancer Group. Trial Co-ordinating Centre. Br J Cancer 1991, 64(6):1151-1156.
15. Xu D.M., Gietema H., de Koning H., Vernhout R., Nackaerts K., Prokop M., et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer 2006, 54(2):177-184.
16. van Iersel C.A., de Koning H.J., Draisma G., Mali W.P., Scholten E.T., Nackaerts K., et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007, 120(4):868-874.
17. Thunnissen F.B., Kerr K.M., Brambilla E., Comin C.E., Franklin W.A., Guldhammerskov B., et al. EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer. Eur Respir J 2006, 28(6):1186-1189.
18. Marcus P.M., Bergstralh E.J., Fagerstrom R.M., Williams D.E., Fontana R., Taylor W.F., et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000, 92(16):1308-1316.
19. Doria-Rose V.P., Marcus P.M., Szabo E., Tockman M.S., Melamed M.R., Prorok P.C. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer 2009, 115(21):5007-5017.
20. Miller A.B., Yurgalevitch S., Weissfeld J.L., Prostate L.C. Death review process in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000, 21(6 Suppl.):400S-406S. Ovarian Cancer Screening Trial Project T.